Seattle Genetics

Seattle Genetics
Share

Seattle Genetics

 •  December 23, 2015

Second of Two Planned Trials Combining ADCETRIS and Opdivo Under Clinical Collaboration Agreement
Seattle Genetics, Inc. (Nasdaq:SGEN) andBristol-Myers Squibb (NYSE:BMY) today announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with...

Seattle Genetics

 •  December 10, 2015

First Clinical Data Presentation of SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with Triple Negative Metastatic Breast Cancer
SAN ANTONIO--(BUSINESS WIRE)--Dec. 10, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A, an...

Seattle Genetics

 •  December 7, 2015

-33A Combination Therapy and Monotherapy Demonstrate Encouraging Anti-leukemic Activity in AML; Data Highlighted in Oral Presentations-
-Planning 33A Phase 3 Trial in Older AML Patients-
ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 7, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted several data presentations at the 57th...

Seattle Genetics

 •  December 7, 2015

-Updated Phase 2 Data Evaluating ADCETRIS in Combination with RCHOP Chemotherapy in Frontline CD30-Expressing High Risk DLBCL Demonstrate an 84 Percent Objective Response Rate with a 76 Percent Complete Remission Rate-
-Updated Phase 1 Data Evaluating ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma...

Seattle Genetics

 •  December 7, 2015

-Final Pivotal Trial Results in Relapsed/Refractory HL Demonstrate Durable Remissions Lasting More than Five Years After ADCETRIS Monotherapy-
-Data From Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for HL-
-ADCETRIS Being Evaluated Broadly in more than 45 HL Clinical Trials-
ORLANDO,...

Seattle Genetics

 •  December 6, 2015

-Updated Data from Phase 1 Clinical Trials Support Further Clinical Evaluation of SGN-CD19A in Randomized Phase 2 Trials: Testing Novel Regimens for Frontline and Relapsed DLBCL-
-First Preclinical Data Presented for SGN-CD19B, a Novel Antibody-Drug Conjugate with PBD Dimer Payload; Phase 1 Clinical Trial in B-cell Malignancies to Begin...

Seattle Genetics

 •  December 2, 2015

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 26th Annual Oppenheimer Healthcare Conference on Wednesday, December 9, at 8:35 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News...

Seattle Genetics

 •  December 1, 2015

BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 1, 2015-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 7, 2015 during the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, FL. Members of Seattle Genetics’ management team and an industry expert...

Seattle Genetics

 •  November 23, 2015

-Trial Based on Anti-Leukemic Activity Observed in Ongoing Phase 1 Clinical Trials Evaluating SGN-CD33A in AML-
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 23, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1/2 clinical trial of SGN-CD33A (vadastuximab talirine) in patients with relapsed or refractory acute...

Seattle Genetics

 •  November 6, 2015

-ADCETRIS Data Featured in 17 Presentations, Including Eight Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Expressing Malignancies- -Clinical Data for SGN-CD33A (Vadastuximab Talirine) and SGN-CD19A (Denintuzumab Mafodotin) ADC Programs to be Highlighted in Oral Presentations- -First Disclosure of Two...